AxSpA is a chronic condition. Symptoms can be alleviated, and joint damage can be prevented by prompt and appropriate treatment. Delay in treatment can lead to limitation in movement of the spine/other joints and hunching of the back which may be permanent.
• Exercise is the cornerstone of treatment – regular stretching can help to reduce pain and stiffness. A physiotherapist will teach you specific exercise routines. In addition, non-spinal loading exercises such as swimming are very useful.
• Non-steroidal anti-inflammatory drugs (NSAIDs) help with pain control and reduction of inflammation.
• Biologics: These are targeted medications for patients with severe disease in whom other treatments including NSAIDs have failed. These are given subcutaneously (injection under the skin given to the thighs or abdomen) or through the veins. Examples include infliximab, adalimumab, golimumab, etanercept, secukinumab, and ixekizumab.
• Other disease-modifying anti-rheumatic drugs (DMARDs) may be given in select patients who have affected joints in the upper or lower limbs. Examples include sulfasalazine and methotrexate.
• Newer targeted synthetic DMARDs have been developed and are usually reserved for patients who have failed NSAIDs and one or more biologics e.g. tofacitinib and upadacitinib.
• Patients on DMARDs will require regular blood tests to monitor for any potential side effects.
AxSpA patients are at higher risk of comorbid conditions such as osteoporosis and cardiovascular disease. These conditions should be addressed as part of holistic care for AxSpA and AS. Certain vaccinations are recommended for patients on biologics to prevent common infections, such as influenza, pneumococcal, RSV and shingles.